A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation
Advanced Science · 2025
DOI: 10.1002/advs.202411737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiaxin Ling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Microbiology, The Biomedical Center, Uppsala University, Uppsala, 75123, Sweden. Hauptthemen laut MEDLINE: SARS-CoV-2, Heparan Sulfate, COVID-19, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Science for Life Laboratory, HORIZON EUROPE European Innovation Council.
Abstract (Originalsprache)
The high transmissibility and mutation ability of coronaviruses enable them to easily escape existing immune protection and also pose a challenge to existing antiviral drugs. Moreover, drugs only targeting viruses cannot always attenuate the “cytokine storm”. Herein, a synthetic heparan sulfate (HS) mimetic, HMSA‐06 is reported, that exhibited antiviral activities against both the SARS‐CoV‐2 prototype and Omicron strains by targeting viral entry and replication. Of particular note, HMSA‐06 demonstrated more potent anti‐SARS‐CoV‐2 effects than PG545 and Roneparstat. SARS‐CoV‐2 is reported to hijack autophagy to facilitate its replication, therefore boosting autophagy can attenuate SARS‐CoV‐2 infection. It is revealed that HMSA‐06, but not a similar HS mimetic that failed to inhibit SARS‐CoV‐2, can upregulate cellular autophagy flux. In addition, HMSA‐06 was found to robustly block the NLRP3‐mediated inflammatory reaction in SARS‐CoV‐2 infected THP‐1 derived macrophages as evidenced by a reduction in inflammasome formation and the subsequent decreased secretion of mature caspase‐1 and IL‐1β. The HMSA‐06's inflammation inhibitory function is further confirmed using a LPS/ATP‐stimulated THP‐1 macrophage model. Altogether, this study has identified a promising HS mimetic to combat SARS‐CoV‐2‐associated diseases by inhibiting viral infection and attenuating viral‐induced inflammatory reaction, providing insights into the development of novel anti‐coronavirus drugs in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Microbiology, The Biomedical Center, Uppsala University, Uppsala, 75123, Sweden.
- Zoonosis Science Center, Uppsala University, Uppsala, 75123, Sweden.
- Istituto Di Ricerche Chimiche e Biochimiche G. Ronzoni, Milan, 20133, Italy.
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
- Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD, 4072, Australia.
- SciLifeLab Uppsala, Uppsala University, Uppsala, 75123, Sweden.
ORCID-Profile: Jinlin Li
Förderung
- Swedish Research Council
- Science for Life Laboratory
- HORIZON EUROPE European Innovation Council
- Cancerfonden
- Åke Wiberg Stiftelse
- Vetenskapsrådet
Zitieren
APA
Ling, J., Lundkvist, Å., Guerrini, M., Ferro, V., Li, J. P., & Li, J. (2025). A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation. Advanced Science. https://doi.org/10.1002/advs.202411737
Vancouver
Ling J, Lundkvist Å, Guerrini M, Ferro V, Li JP, Li J. A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation. Advanced Science. 2025. doi:10.1002/advs.202411737
BibTeX
@article{Ling2025,
author = {Ling, Jiaxin and Lundkvist, Åke and Guerrini, Marco and Ferro, Vito and Li, Jin-Ping and Li, Jinlin},
title = {A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411737}
}
EUVIMED